Monoclonal Antibodies Against NS2B of Japanese Encephalitis Virus

2015 ◽  
Vol 34 (2) ◽  
pp. 96-100
Author(s):  
Qian Dong ◽  
Qiuping Xu ◽  
Xindi Ruan ◽  
Shaomei Huang ◽  
Shengbo Cao
Keyword(s):  
Monoclonal Antibodies ◽  
Japanese Encephalitis Virus ◽  
Japanese Encephalitis ◽  
Encephalitis Virus

scholarly journals Antigenic Analysis of Japanese Encephalitis Virus Using Monoclonal Antibodies

1983 ◽  
Vol 57 (6) ◽  
pp. 519-530
Author(s):  
Yuzuru KOBAYASHI ◽  
Hitoshi HASEGAWA ◽  
Takashi OYAMA ◽  
Tomonori TAMAI ◽  
Tomoo SHIROGUCHI ◽  
...  
Keyword(s):  
Monoclonal Antibodies ◽  
Japanese Encephalitis Virus ◽  
Japanese Encephalitis ◽  
Encephalitis Virus ◽  
Antigenic Analysis

Monoclonal Antibodies Against NS4B Protein of Japanese Encephalitis Virus

2013 ◽  
Vol 32 (6) ◽  
pp. 382-385 ◽  
Author(s):  
Xindi Ruan ◽  
Shaomei Huang ◽  
Lin Shao ◽  
Jing Ye ◽  
Zheng Chen ◽  
...  
Keyword(s):  
Monoclonal Antibodies ◽  
Japanese Encephalitis Virus ◽  
Japanese Encephalitis ◽  
Encephalitis Virus ◽  
Ns4b Protein

scholarly journals Protection of mice against Japanese encephalitis virus group II strain infections by combinations of monoclonal antibodies to different antigenic domains on glycoprotein E

2012 ◽  
Vol 3 (2) ◽  
pp. 17
Author(s):  
Ashok Kumar Gupta ◽  
Attiyaril Abraham Koshy ◽  
Vaibhavi Jawahar Lad
Keyword(s):  
Monoclonal Antibodies ◽  
Protective Effect ◽  
Japanese Encephalitis Virus ◽  
Japanese Encephalitis ◽  
Encephalitis Virus ◽  
Glycoprotein E ◽  
Antigenic Domains ◽  
Group Ii ◽  
Antigenic Epitopes ◽  
Group 1

A combination of at least three hemagglutination- inhibition-positive (HAI) and virus-specific (Hs) monoclonal antibodies (MAbs) to glycoprotein E (gpE) of Japanese encephalitis virus (JEV) fully protected (100%) mice against JEV strain 733913 infections (group 1). However, these representative epitopes are reported to have been lost on JEV group II strains. In the present study, therefore, the protective effect of various combinations of anti-gpE MAbs representing antigenic epitopes other than Hs was studied on mice infections with JEV group II strains: JEV strains 641686 and 691004. MAbs used in the protective experiments were characterized as HAI-negative virus-specific (NHs) and HAI-positive flavivirus cross-reactive (Hx). Additionally, one of the Hs MAbs (MAb Hs-3) was included in the experiments. Mice were first administered single MAbs or their combinations intraperitoneally and 24 h later, infected with the virus intracerebrally. Protection rates of 70-75% were obtained with a combination of four MAbs: MAbs NHs-1, Hx-1, Hx-3 and Hs-3. However, protection rates of only 20-40% were obtained with three MAbs but none was observed with single or two MAbs. There was, however, a substantial increase in mice survival. The protective effect of several combinations of anti-gpE MAbs representing different antigenic epitopes might be due to the enhancement of binding within the same group and also between different MAb groups. The present results indicate that NHs and Hx epitopes should be incorporated with three Hs epitopes in a JEV vaccine that would have an added advantage, particularly in the flaviviral endemic areas with JEV strain variations.

scholarly journals Humanized Monoclonal Antibodies Derived from Chimpanzee Fabs Protect against Japanese Encephalitis Virus In Vitro and In Vivo

2008 ◽  
Vol 82 (14) ◽  
pp. 7009-7021 ◽  
Author(s):  
Ana P. Goncalvez ◽  
Cheng-Hsin Chien ◽  
Kamolchanok Tubthong ◽  
Inna Gorshkova ◽  
Carrie Roll ◽  
...  
Keyword(s):  
Monoclonal Antibodies ◽  
Japanese Encephalitis Virus ◽  
Japanese Encephalitis ◽  
Neutralizing Antibodies ◽  
Therapeutic Potential ◽  
Encephalitis Virus ◽  
Domain Iii ◽  
Humanized Monoclonal Antibodies

ABSTRACT Japanese encephalitis virus (JEV)-specific Fab antibodies were recovered by repertoire cloning from chimpanzees initially immunized with inactivated JE-VAX and then boosted with attenuated JEV SA14-14-2. From a panel of 11 Fabs recovered by different panning strategies, three highly potent neutralizing antibodies, termed Fabs A3, B2, and E3, which recognized spatially separated regions on the virion, were identified. These antibodies reacted with epitopes in different domains: the major determinant for Fab A3 was Lys179 (domain I), that for Fab B2 was Ile126 (domain II), and that for Fab E3 was Gly302 (domain III) in the envelope protein, suggesting that these antibodies neutralize the virus by different mechanisms. Potent neutralizing antibodies reacted with a low number of binding sites available on the virion. These three Fabs and derived humanized monoclonal antibodies (MAbs) exhibited high neutralizing activities against a broad spectrum of JEV genotype strains. Demonstration of antibody-mediated protection of JEV infection in vivo is provided using the mouse encephalitis model. MAb B2 was most potent, with a 50% protective dose (ED50) of 0.84 μg, followed by MAb A3 (ED50 of 5.8 μg) and then MAb E3 (ED50 of 24.7 μg) for a 4-week-old mouse. Administration of 200 μg/mouse of MAb B2 1 day after otherwise lethal JEV infection protected 50% of mice and significantly prolonged the average survival time compared to that of mice in the unprotected group, suggesting a therapeutic potential for use of MAb B2 in humans.

Sign in / Sign up

Export Citation Format

Share Document